Biology Reference
In-Depth Information
Conclusions
In conclusion, although antigenicity of EPO is probably high,the number of
cases of rHuEPO-induced antibody formation remains very low compared
with the very high number of patients treated with rHuEPO. Nevertheless, the
sharp increase of such cases during the past few years shows that highly strin-
gent quality control processes are absolutely required to keep this drug safe.
Whether these cases will lead to the identification of a patient sub-population
in which special care must be taken when prescribing rHuEPO is now the main
question. If this question can be answered,significant good would have come
from a regrettable situation.
References
1Piercy R, Swardson C, Hinchcliff K (1998) Erythroid hypoplasia and anemia following adminis-
tration of recombinant human erythropoietin to two horses.
J Am Vet Med Assoc
212: 244-247
2 Coscarella A, Liddi R, Di LM, Bach S, Faiella A, van der Meide PH, Mele A, De Santis R (1998)
The rhGM-CSF-EPO hybrid protein MEN 11300 induces anti-EPO antibodies and severe anaemia
in rhesus monkeys.
Cytokine
10: 964-969
3 Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo
V, Teyssandier I et al. (2002) Pure red-cell aplasia and anti-erythropoietin antibodies in patients
treated with recombinant erythropoietin.
N Engl J Med
346: 469-475
4Sytkowski A, Feldman L, Zurbuch D (1991) Biological activity and structural stability of N-deg-
lycosylated recombinant human erythropoietin.
Biochem Biophys Res Commun
176: 698-704
5 Delorme E, Lorenzini T, Giffin J, Martin F, Jacobsen F, Boone T, Elliott S (1992) Role of glyco-
sylation on the secretion and biological activity of erythropoietin.
Biochemistry
31: 9871-9876
6Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, Zhan H, Osslund TD, Chirino AJ, Zhang
J et al. (1998) Efficiency of signalling through cytokine receptors depends critically on receptor
orientation.
Nature
395: 511-516
7 Skibeli V, N issen-Lie G, Torjesen P (2001) Sugar profiling proves that human serum erythropoi-
etin differs from recombinant human erythropoietin.
Blood
98: 3626-3634
8 Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P (1996) Auto-antibod-
ies against erythropoietin in a patient with pure red-cell aplasia.
N Engl J Med
334: 630-633
9 Komatsu N, Nakauchi H, Miwa A, Ishihara T, Eguchi M, Moroi M, Okada M, Sato Y, Wada H,
Yawata Y (1991) Establishment and characterization of a human leukemic cell line with
megakaryocytic features: Dependency on granulocyte-macrophage colony stimulating factor,
interleukin 3, or erythropoietin for growth and survival.
Cancer Res
51: 341-348
10 Castelli G, Famularo A, Semino C, Machi A, Ceci A, Cannella G, Melioli G (2000) Detection of
anti-erythropoietin antibodies in haemodialysis patients treated with recombinant human-erythro-
poietin.
Pharmacol Res
41: 313-318
11 Urra JM, de la Torre M, Alcazar R, Peces R (1997) Rapid method for detection of anti-recombi-
nant human erythropoietin antibodies as a new form of erythropoietin resistance.
Clin Chem
43:
848-849
12 Prabhakar S, Muhlfelder T (1997) Antibodies to recombinant human erythropoietin causing pure
red cell aplasia.
Clin Nephrol
47: 331-335
13 Linardaki GD, Boki KA, Fertakis A, Tzioufas AG (1999) Pure red cell aplasia as presentation of
systemic lupus erythematosus: Antibodies to erythropoietin.
Scand. J Rheumatol
28: 189-191
14 Peschle C, Marmont AM, Marone G, Genovese A, Sasso GF, Condorelli M (1975) Pure red cell
aplasia: Studies on an IgG serum inhibitor neutralizing erythropoietin.
Br J Haematol
30:
411-417
15 Marmont A, Peschle C, Sanguineti M, Condorelli M (1975) Pure red cell aplasia (PRCA):
Response of three patients of cyclophosphamide and/or antilymphocyte globulin (ALG) and
demonstration of two types of serum IgG inhibitors to erythropoiesis.
Blood
45: 247-261
